Compare SANA & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANA | ATEC |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2021 | 2006 |
| Metric | SANA | ATEC |
|---|---|---|
| Price | $3.22 | $11.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $7.60 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 2.6M | 2.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.24 | 15.04 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $101,739,000.00 |
| Revenue This Year | N/A | $18.97 |
| Revenue Next Year | N/A | $16.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.42 | $9.25 |
| 52 Week High | $6.55 | $23.29 |
| Indicator | SANA | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 44.46 |
| Support Level | $3.16 | $10.21 |
| Resistance Level | $3.36 | $13.08 |
| Average True Range (ATR) | 0.22 | 0.55 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 72.67 | 46.90 |
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.